Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
NDMA formation due to active ingredient degradation and nitrite traces in drug product
ID
Golob, Nejc
(
Author
),
ID
Peterlin, Simona
(
Author
),
ID
Grahek, Rok
(
Author
),
ID
Roškar, Robert
(
Author
)
PDF - Presentation file,
Download
(1,30 MB)
MD5: D268C6B83026B705F8EA90E0DE7E161E
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/pii/S0022354923001077
Image galllery
Abstract
N-nitrosamines are genotoxic compounds which can be found as impurities in drug substances and drug products used in the pharmaceutical industry. To date, several possible nitrosamine sources in drug products have been reported and this study aims to illuminate another one. A case of afatinib drug product was investigated, in which up to 50 ppb N-nitrosodimethylamine (NDMA) traces were detected. Afatinib was found to degrade to the secondary amine dimethylamine (DMA), forming NDMA with traces of nitrite in crospovidone. Two series of film-coated tablets were prepared with crospovidone from two different manufacturers, containing different levels of nitrites. Tablets were subjected to an accelerated stability study (40 °C/75% relative humidity) or stored at room temperature and levels of NDMA, DMA and nitrite in tablets were monitored. NDMA and nitrite were found on ppb levels, whereas DMA was detected on ppm levels. NDMA formation in the drug product was found to be time, temperature and nitrite dependent and it was emphasized that DMA and nitrite should be reduced. The accelerated stability study proved to be a useful tool for predicting nitrosamine formation in the drug product.
Language:
English
Keywords:
N-nitrosodimethylamine
,
NDMA
,
afatinib drug product
,
drug substance degradation
,
dimethylamine
,
DMA
,
nitrite
,
excipient
,
crospovidone
,
stability study
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2023
Number of pages:
Str. 1277-1286
Numbering:
Vol. 112, iss. 5
PID:
20.500.12556/RUL-148688
UDC:
661.12
ISSN on article:
0022-3549
DOI:
10.1016/j.xphs.2023.03.007
COBISS.SI-ID:
146220547
Publication date in RUL:
29.08.2023
Views:
504
Downloads:
188
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Journal of pharmaceutical sciences
Shortened title:
J. pharm. sci.
Publisher:
Elsevier, American Pharmacists Association
ISSN:
0022-3549
COBISS.SI-ID:
25777152
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
N-nitrozodimetilamin
,
NDMA
,
zdravilo afatinib
,
razgradnja zdravilne učinkovine
,
dimetilamin
,
DMA
,
nitriti
,
pomožne snovi
,
krospovidon
,
stabilnostne študije
,
farmacevtska industrija
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back